Cargando…
Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
PURPOSE: Tiotropium/olodaterol (TIO/OLO) fixed-dose combination (FDC) can improve lung function and quality of life for patients with chronic obstructive pulmonary disease (COPD), and is not inferior to other LAMA/LABAs. The aim of this study was to assess the cost-effectiveness of TIO/OLO FDC in pa...
Autores principales: | Lan, Ying, Yang, Nan, Wang, Yirong, Yang, Yan, Xu, Min, He, Qin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520256/ https://www.ncbi.nlm.nih.gov/pubmed/37767047 http://dx.doi.org/10.2147/COPD.S425409 |
Ejemplares similares
-
Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016) -
Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019) -
Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018) -
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
por: Buhl, Roland, et al.
Publicado: (2015) -
Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
Publicado: (2018)